Table of Contents 33 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) (cid:0) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR (cid:0) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38944 Akero Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 81-52 ...

Exhibit 99.1 Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update — Statistically significant week 96 results from the Phase 2b HARMONY study of EFX in patients with pre-cirrhotic MASH reported during the first quarter of 2024 — — Phase 3 SYNCHRONY Histology and SYNCHRONY Real-World studies in patients with pre-cirrhotic MASH (F2-F3) continue to enroll; SYNCHRONY Outcomes study in patients with compensated cirrhosis due to MASH (F4) on track to be initiated in second ...

-- Statistically significant week 96 results from the Phase 2b HARMONY study of EFX in patients with pre-cirrhotic MASH reported during the first quarter of 2024 -- -- Phase 3 SYNCHRONY Histology and SYNCHRONY Real-World studies in patients with pre-cirrhotic MASH (F2-F3) continue to enroll; SYNCHRONY Outcomes study in patients with compensated cirrhosis due to MASH (F4) on track to be initiated in second quarter of 2024 -- SOUTH SAN FRANCISCO, Calif., May 10, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, In ...

MILWAUKEE, April 2, 2024 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Akero (Nasdaq: AKRO). The investigation results from inaccurate statements Akero may have made regarding its business operations and prospects. Click here to learn more about the investigation: https://www.ademilaw.com/case/akero-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you. The investigation focuses on Akero's representations regarding its Phas ...

SOUTH SAN FRANCISCO, Calif., March 08, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ:AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the closing of its previously announced underwritten public offering of 12,650,000 shares of its common stock at a public offering price of $29.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to a ...

Akero Therapeutics公司概况 - Akero Therapeutics是一家临床阶段的公司，专注于为严重代谢疾病患者开发变革性治疗方案[9] EFX药物研究 - EFX是Akero的主力产品候选药物，目前正在进行两项进行中的Phase 3临床试验[9] - EFX似乎能够减少肝脏脂肪和炎症，逆转纤维化，增加胰岛素敏感性和改善脂质代谢[6] - EFX的综合治疗方式有望改善MASH的复杂多系统疾病状态，包括改善与心血管疾病相关的脂蛋白风险因素[6] - EFX的研究结果显示，与GLP-1RA单独治疗相比，EFX加GLP-1RA治疗12周后，肝脏健康的非侵入性标志物有明显改善[5] - EFX加GLP-1RA治疗组的患者在非侵入性肝损伤和纤维化标志物方面的改善更明显，反映了EFX与GLP-1RA结合时的互补胰岛素敏感作用[5] - EFX加GLP-1RA治疗组的患者体重减少与GLP-1RA单独治疗组相似[4] - EFX加GLP-1RA治疗组的患者肝脂肪减少幅度更大，肝脂肪水平几乎在90%的患者中得到正常化[5]

Akero Therapeutics公开发行股票 - Akero Therapeutics宣布定价11,000,000股普通股的公开发行，每股价格为$29.00[1] - J.P. Morgan、摩根士丹利、Jefferies和Evercore ISI担任本次发行的联席主承销商[2] - Akero Therapeutics根据之前向美国证券交易委员会（SEC）提交的有效的自动生效的注册声明发行普通股[3] - 关于本次发行的初步招股说明书和相关招股说明书已于2024年3月4日向SEC提交[4]

Akero Therapeutics, Inc. (AKRO) announced a statistically significant histological improvement in the primary endpoint of its mid-stage study, evaluating the efficacy and safety of efruxifermin (EFX) in patients with pre-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH), fibrosis stage 2 or 3, at week 96.EFX, the company’s lead product candidate, is being developed for a serious liver disease caused by metabolic dysregulation that does not have any approved therapies.We remind the investors ...

公开发行 - Akero Therapeutics宣布启动了一项3亿美元普通股公开发行[1] - J.P. Morgan、摩根士丹利、Jefferies和Evercore ISI将担任联席承销商[2] - 该公司将根据之前向美国证券交易委员会（SEC）提交的有效无需注册声明进行证券发行[3] 公司业务 - Akero Therapeutics正在开发治疗严重代谢疾病的转型性治疗方法[5]

alfexe/iStock via Getty Images Akero Therapeutics, Inc. (NASDAQ:AKRO) has been able to report positive results from its phase 2b HARMONY study, which used its drug efruxifermin [EFX] for the treatment of patients with pre-cirrhotic MASH or Metabolic dysfunction-associated steatohepatitis with stage 2 or 3 fibrosis. The significance of this is that it is already in the process of testing out this drug in a phase 3 program known as SYNCHRONY. Patients have already been dosed in the first two phase 3 studi ...